Cell therapy weekly: Eterna Therapeutics enters research collaboration to advance cell therapies for cancer
This week: Eterna Therapeutics enters research collaboration to advance cell therapies for cancer, Chief Financial Officer of Lineage Cell Therapeutics appointed and ElevateBio unveils LentiPeak™ lentiviral vector platform.
The news highlights:
Eterna Therapeutics enters research collaboration to advance cell therapies for cancer
Eterna Therapeutics (CA, USA) has entered a sponsored research agreement with Michael Andreeff, Professor of Leukemia at the University of Texas MD Anderson Cancer Center (USA), with the goal of accelerating the development of the company’s therapeutic candidates for the treatment of various cancers including acute myeloid leukemia and solid tumors. Under the terms of the agreement, Andreeff will evaluate the capacity of gene-edited iPSC therapeutic candidates to stimulate advanced immune responses in vivo.
“We are excited to announce this research agreement to advance a central pillar of Eterna’s pipeline: allogeneic cell therapies for the treatment of cancer,” stated Matt Angel, Interim CEO of Eterna. “This work has the potential to accelerate and expand the applications of the allogeneic cell therapy platform that we obtained last year through our acquisition of Novellus Therapeutics.”
Chief Financial Officer of Lineage Cell Therapeutics appointed
Lineage Cell Therapeutics (CA, USA) a clinical-stage biotechnology company developing novel allogeneic cell therapies, has appointed Jill Howe as the company’s Chief Financial Officer. Howe most recently served as Chief Financial Officer of DTx Pharma (CA, USA) and prior to that was Vice President of Finance at Gossamer Bio (CA, USA).
“Jill is a wonderful addition to our executive team as we work to establish Lineage as a leader in cell therapy and cell transplant medicine,” stated Brian M. Culley, CEO of Lineage Cell Therapeutics. “She is a successful executive with an extensive track record of execution in capital raising, strategic financial management, global expansion, and support, as well as mergers & acquisitions, and reflects the newest expansion of our team. Our continued growth will allow Lineage to exhibit greater productivity and increase the breadth of what we are able to accomplish in the months and years ahead.”
ElevateBio unveils LentiPeak™ lentiviral vector platform
ElevateBio, (MA, USA), a technology-driven company committed to powering the development of transformative cell and gene therapies, unveiled ElevateBio BaseCamp’s proprietary LentiPeak lentiviral vector platform. LentiPeak is a serum-free, suspension-based, scalable production platform that aims to facilitate smooth transition of cell and gene therapies from preclinical to commercialization stages.
“As a 30-year veteran of the cell and gene therapy industry, I’ve witnessed the immense advancement of lentiviral vector technology from its infancy to the current landscape with six FDA-approved lentiviral vector-derived cell and gene therapies,” stated Mitchell Finer, Co-founder and President of Research and Development at ElevateBio. “The LentiPeak platform is made possible by ElevateBio’s strong scientific foundation, industry-leading expertise, and the investments we’ve made into viral vector production. Our pioneering work continues to be the basis for our continued innovation to drive many more therapies through development to commercialization for our partners.”
You might also like: